• NeuroPace's third-quarter 2026 net loss from continuing operations narrowed 33% year over year to $3.3 million.
• Revenue fell year over year to $23.1 million, with management attributing the shortfall to account-level issues and field-organization disruption.
• The company submitted Remote Care for FDA review to enable physicians to program the RNS System through telehealth.
• Full-year 2026 revenue guidance was cut to $91 million-$92 million from $99.5 million-$101.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261112017708) on November 12, 2026, and is solely responsible for the information contained therein.